Metastatic Testicular Cancer: What to Ask

NCI states it directly. It is the most important sentence on this page. Even patients with widespread spread at diagnosis may have curable disease. That includes patients with brain metastases. NCI says they should be treated with cure as the intent.

Metastatic testicular cancer is not like most other advanced solid tumors. The goal usually stays cure. That shapes every question below.

Two systems are in use at once. Regular staging is one. The other is the International Germ Cell Cancer Consensus Group classification. It is used for men with distant spread, or with bulky disease in the retroperitoneum.

That second system shapes the chemotherapy. It runs on three inputs:

• Histology: seminoma or nonseminoma.
• How far the disease has spread. The steps run from testis only, to retroperitoneal nodes, to lung or distant node spread, to organs other than the lungs.
• For nonseminomas, how high the serum markers are.

Seminoma uses only two groups. The dividing line is simple. Is there spread to organs other than the lungs?

• Good risk. Spread limited to lymph nodes and lungs. Five-year progression-free survival 82%, overall survival 86%.
• Intermediate risk. Spread to organs other than the lungs. Five-year progression-free survival 67%, overall survival 72%.

There is no poor-risk group for seminoma.

Three groups here, and three factors decide.

• Good risk. A testis or retroperitoneal primary tumor, spread limited to lymph nodes and lungs, and markers in the good-risk range.
• Intermediate risk. Markers in the intermediate range.
• Poor risk. Any of three things: a mediastinal primary tumor, spread to organs other than the lungs, or very highly raised markers.

Where the tumor started is a real prognostic factor. It is not a technicality. The mediastinum is the space in the middle of the chest, between the lungs. A germ cell tumor that starts there carries a worse outlook than one starting in the testis.

The survival numbers have improved. The 1997 analysis created these groups. Its 5-year overall survival figures were 92%, 80%, and 48%. A 2006 pooled analysis of chemotherapy trials reported 94%, 83%, and 71%. Progression-free survival in 1997 ran 89%, 75%, and 41%.

BEP is bleomycin, etoposide, and cisplatin. Four cycles became the standard after one randomized trial. It showed similar outcomes to the older PVB regimen, with fewer toxic effects.

Two questions are worth asking by name.

Three cycles or four? Two randomized trials compared three cycles with four in good-risk disease. Neither found a significant benefit from the longer course. For intermediate and poor risk, four is standard. None of this is a rule you can apply to yourself from a page: the count follows your IGCCCG group, whether the tumour is seminoma or nonseminoma, how fast your markers are falling, and what your lungs and kidneys can take.

Can bleomycin be dropped? This is genuinely debated. The evidence tilts against dropping it. One randomized trial compared three cycles of BEP with three cycles of EP. EP is etoposide and cisplatin, without bleomycin. Overall survival was 95% with BEP and 86% with EP. A separate trial of more than 260 patients compared three cycles of BEP with four cycles of EP. The bleomycin arm had 6 relapses and 5 deaths. The EP arm had 14 relapses and 12 deaths. That gap was not statistically significant. NCI notes a pattern, though. In every trial of this comparison, the survival trend favored the bleomycin arm.

VIP is the other alternative. It is etoposide, ifosfamide, and cisplatin. Two randomized trials compared it with BEP in intermediate- and poor-risk disease. Overall survival and time to treatment failure were similar. Blood count toxicity was much worse with VIP.

For poor-risk disease, many attempts to beat BEP have failed. The most recent tested a switch after two cycles. One arm got four cycles of BEP. The other got two cycles of BEP, then two cycles of high-dose cyclophosphamide, etoposide, and carboplatin. There was no survival difference. Earlier trials of higher-dose cisplatin, or of long-term maintenance chemotherapy, also disappointed.

A rise in AFP or beta-hCG matters when it is clear and unambiguous. In most cases it signals a relapsed germ cell tumor. NCI states that this alone is an indication for treatment. Imaging evidence is not required.

That cuts both ways. Marker rises still need careful reading. The same false-positive traps apply as at diagnosis. Tests can cross-react with luteinizing hormone. Marijuana use has been reported to raise beta-hCG. And AFP is mildly raised long-term in some people, or by liver disease.

LDH behaves differently here than during surveillance. In metastatic nonseminoma, large prognostic model studies found LDH to be a significant independent predictor of survival.

Sometimes chemotherapy starts before the testicle comes out. That happens when the diagnosis came from a biopsy elsewhere, or from markers plus imaging. Ask about orchiectomy afterward. NCI explains why it is generally still done. Chemotherapy may not clear the primary tumor. Case reports describe live tumor found at surgery afterward, even when the metastases responded completely.

Sperm banking belongs in the first conversation, not the third. Cisplatin-based chemotherapy affects fertility. The window before treatment starts is short.

Where treatment happens also matters. One analysis covered 380 patients on the same protocol at 49 institutions, in two European trial groups. Outcomes varied by institution. That is a fair reason to ask how many germ cell tumors a center treats. It is also a fair reason to ask for a tumor board review.

Our page on testicular cancer covers the basics, and the treatment question list covers the earlier decisions.

BEP chemotherapy carries two risks that need a plan before they happen.

• Call 911 or go to an emergency department if you have new trouble breathing, shortness of breath, or wheezing. Bleomycin can cause severe lung injury, and the drug label lists these as symptoms to act on at once.
• Call your oncology team immediately, at any hour, if you have a temperature of 100.4°F (38°C) or higher, or chills and shaking, during or after a cycle. Neutrophil counts fall after cisplatin-based chemotherapy, and fever at that point is an emergency, not something that waits for morning. If you cannot reach them quickly, go to an emergency department and say at the door that you are having chemotherapy, so antibiotics are started quickly.
• Call your care team the same day if you develop a dry cough that is new since chemotherapy started, even without fever. Cough is on the same bleomycin warning list as breathlessness.
• Call your care team within a day or two if you notice new ringing in the ears, muffled hearing, or a big drop in how much you are passing urine. Cisplatin affects hearing and the kidneys, and both are easier to protect early.
• Call your care team within a day or two if a new lump, new back pain, or a marker result you were told about does not fit the plan you were given. A clear rise in AFP or beta-hCG is on its own a reason to treat, so it is not something to hold until the next routine visit.

• National Cancer Institute, Testicular Cancer Treatment (PDQ) - Health Professional Version, updated May 16, 2025, accessed August 6, 2026
• National Cancer Institute, Testicular Cancer Treatment (PDQ) - Patient Version, accessed August 6, 2026
• MedlinePlus, Bleomycin Injection, accessed August 11, 2026
• StatPearls (NCBI Bookshelf), Neutropenic Fever, accessed August 11, 2026